Gumucio JP, Flood MD, Phan AC, Brooks SV, Mendias CL. Targeted inhibition of TGF-␤ results in an initial improvement but long-term deficit in force production after contraction-induced skeletal muscle injury.
LENGTHENING CONTRACTION-INDUCED injuries to skeletal muscle tissue are among the most common injuries that are treated in the sports medicine setting (23, 46) . For patients that suffer moderate and severe injuries, there is often a persistent atrophy of muscle fibers, an accumulation of fibrotic scar tissue in the extracellular matrix (ECM), and a decrease in muscle strength, functional capacity, and athletic ability (15, 46) . These patients are also much more likely to have repeated muscle injuries, with each subsequent injury resulting in greater muscle atrophy and scar tissue deposition (5, 20, 46) . Current treatments for muscle injuries are focused on relieving pain and having patients complete a prescribed program of therapy and rehabilitation, but these therapies have limited efficacy in preventing muscle atrophy and fibrosis following injury (16) . Identifying new therapies that prevent muscle atrophy and fibrosis following injury have the potential to greatly improve functional outcomes in patients with severe muscle injuries.
Transforming growth factor-␤1 (TGF-␤) is a cytokine with well-documented roles in promoting inflammation and fibrosis (21, 22) . TGF-␤ is secreted from cells as part of the large latent complex (LLC) that, in addition to TGF-␤, consists of latencyassociated protein (LAP) and latent TGF-␤-binding protein 1 (LTBP-1). The LLC binds to other ECM components like fibrillin-1 and fibronectin and provides a local reservoir of latent TGF-␤ in the ECM (2) . Active TGF-␤ can be released from the LLC through mechanical force or proteolytic degradation of LAP or LTBP-1 (14) . Once liberated, active TGF-␤ binds to the type II and type I TGF-␤ receptors to activate intracellular Smad2/3 and TAK1-p38 MAPK pathways (48) .
Following injury to skeletal muscles, there is an increase in the expression of TGF-␤ (47) , and the administration of TGF-␤ into otherwise healthy muscles of mice leads to a reduction in muscle force production, an increase in the levels of type I collagen, atrogin-1, and scleraxis, and an accumulation of intermyocellular fibroblasts (30) . Type I collagen is the major fibrillar collagen in the muscle ECM (4), and atrogin-1 is an E3 ubiquitin ligase that is a rate-limiting enzyme for muscle protein degradation (43) . Scleraxis is a basic HLH (bHLH) transcription factor expressed in connective tissue fibroblasts and is associated with increased fibroblast proliferation and matrix production (25, 29) . Based on the role that TGF-␤ plays in promoting muscle atrophy and fibrosis, we hypothesized that the targeted inhibition of TGF-␤ would improve force production and enhance regeneration after contraction-induced injury. To test this hypothesis, we administered a monoclonal bioneutralizing antibody against TGF-␤ to mice that were subjected to a physiologically relevant contraction-induced injury and measured muscle force production and the expression of genes involved in muscle atrophy and fibrosis at several time points throughout the course of recovery.
METHODS
Animals. This study was approved by University of Michigan Institutional Animal Care and Use Committee and followed the American Physiological Society guidelines for the appropriate use and care of animals in research. Nine-month-old C57Bl/6 mice (n ϭ 30 mice total, 5 mice in each group) were used in this study. During all experiments, mice were anesthetized with 1.5% isofluorane.
In situ muscle contractility measurements. Muscle contractility was performed as previously described (24) . Mice were anesthetized and placed on a platform warmed with a 37°C circulating water bath. The distal portion of the left extensor digitorum longus (EDL) tendon was exposed with a 2-mm skin incision, and a 5-0 silk suture was passed under the tendon. The small exposed area was kept moist with frequent administration of 0.9% NaCl between muscle contractility measurements. The left knee was secured using a blunt screw, and the foot was tightly taped to the platform. The tendon was then tied to the lever arm of a servomotor (Aurora Scientific) that controlled the length of the muscle and also measured the generation of force. The EDL muscle was activated using an isolated stimulator (Aurora Scientific) and fine subdermal platinum needle electrodes (Grass Instruments) that flanked the peroneal nerve. A stimulation current of 6 mA and a pulse duration of 0.2 ms was used for all contractions. The length of the muscle was adjusted to reach optimum muscle length (L o), which was determined as the length of muscle that generated maximum twitch force production and then measured from the tibial tuberosity through the distal myotendinous junction. Optimal muscle fiber length (L f) was determined by multiplying Lo by the previously determined Lf/Lo ratio of 0.44 (6) . Tetanic contractions were generated during trains of pulses starting at a frequency of 50 Hz and in equal increments during successive trains until the force level plateaued (P o), typically at 150 Hz. One-minute rest periods were allowed between isometric contractions. Baseline Po values for the control group were 396 Ϯ 20.0 mN and for the TGF-␤ inhibitor group were 423 Ϯ 27.6 mN. Using a t-test (␣ ϭ 0.05), there was not a significant difference between these two values, and we therefore present the mean baseline value in RESULTS.
Contraction-induced injury. After determining P o, muscles underwent a series of 80 active lengthening contractions to induce injury. Active stretches were initiated at Lo, were of 20% strain relative to Lf at a velocity of 1.0 Lf/s, and commenced 100 ms after the onset of maximum stimulation. Four sets of 20 lengthening contractions were performed, with 5 min of rest between each set and 15 s of rest between each lengthening contraction repetition. Following the injury protocol, the small incision at the ankle was closed with 7-0 monofilament nylon suture and bathed with povidone-iodine solution, and the mice were monitored until they recovered from anesthesia.
Antibody treatment. Mice were divided into two cohorts. The experimental cohort received a murine bioneutralizing monoclonal IgG1 antibody against TGF-␤, 1D11, (BioXCell) while the control cohort received a nonspecific murine monoclonal IgG1 antibody, MOPC21 (BioXCell). 1D11 can bind and neutralize the activity of all three isoforms of TGF-␤ (10, 49) . Intraperitoneal injections of 1D11 or MOPC21 were given at a dose of 10 mg/kg immediately after injury and at 3 and 6 days postinjury to block TGF-␤ signaling during the acute phases of muscle injury. This dose was chosen based on previous studies that demonstrated the ability of a 10 mg/kg dose of 1D11 to prevent fibrosis in the muscles of mdx mice (1) and in the lungs of hyperoxic gas-injured mice (36) . After a period of 3, 7, or 21 days following administration of the lengthening contractions, mice were anesthetized, and P o was again measured and compared with the preinjury Po value. Following the measurement of Po, muscles were isolated for immunohistochemistry and gene expression analysis, and mice were humanely killed by cervical dislocation followed by the creation of a bilateral pneumothorax.
Histology. The distal half of the EDL was snap-frozen in TissueTek (Sakura) using isopentane cooled in liquid nitrogen and stored at Ϫ80°C until use. Muscles were sectioned at a thickness of 10 m and permeabilized in 0.2% Triton X-100 in PBS, blocked in 5% goat serum, and incubated with DAPI (Sigma) to identify nuclei and biotinylated antibodies against type I collagen (catalog no. ab6577; Abcam) to label ECM. Primary antibodies were detected with FITC conjugated to streptavidin (Invitrogen). Sections were visualized using a Axioplan 2 (Zeiss) microscope equipped with an AxioCam camera. For quantitative histomorphometry, three random fields per muscle sample taken using a ϫ20 objective were subjected to analysis. All quantification was performed using ImageJ (National Institutes of Health).
Gene expression. RNA was isolated from EDL muscles using an miRNeasy kit (Qiagen) and treated with DNase I (Qiagen). RNA integrity was verified using a Bioanalyzer RNA system (Agilent). Approximately 200 ng of RNA was reverse transcribed using an iScript RT kit with a combination of oligo(dT) 15 and random hexamer primers (Bio-Rad) and amplified in a CFX96 real-time thermal cycler (Bio-Rad) with SsoFast EvaGreen supermix (Bio-Rad) using primers for atrogin-1, types I and III collagen, fibroblast specific protein-1 (FSP-1), scleraxis, and tenomodulin. The concentration of primers was 500 nM. Expression of mRNA transcripts was normalized to ␤ 2-microglobulin, and further normalized to the 3-day control group using the methods of Schmittgen and Livak (44) . ␤2-Microglobulin was selected as a housekeeping gene based on its stable expression in skeletal muscle tissue and because ␤2-microglobulin expression did not differ between treatment groups (26, 32, 45) . The presence of single amplicons from qPCR reactions was verified using meltingcurve analysis as well as electrophoresis using a 2% agarose gel. The sequences for primers are listed in Table 1 .
Statistical analysis. Data are presented as means Ϯ SE. A two-way ANOVA (␣ ϭ 0.05) was used to determine the differences between groups with respect to time and treatment. Holm-Sidak post hoc sorting was used to identify differences between specific groups. All analysis was performed in Prism 6.0 (GraphPad Software).
RESULTS
Before injury, the baseline mean force production of EDL muscles for both groups was 408 Ϯ 17.2 mN. Following injury, compared with control mice, mice that received TGF-␤ inhibitor had no differences in muscle mass at any time point (Table 2 ). Despite no difference in muscle mass, P o for mice that received TGF-␤ inhibitor was significantly greater at both 3 and 7 days postinjury than the values for control mice (Fig. 1) . Control mice displayed a significant increase in P o between 7 and 21 days after injury, reaching a force value that was similar to the preinjury value (Fig. 1) . In contrast, mice that received the TGF-␤ inhibitor showed no increase in force between 7 and 21 days, and P o at 21 days was significantly lower than the force value achieved by control mice, recovering to only ϳ75% of the preinjury force values (Fig. 1) . Time to peak tension and half-relaxation time were not different between groups at any time point (Table 2 ). There were differences in the maximum rate of force development, although these differences are likely reflective of changes in P o as opposed to an inherent change in the rate at which force is developed.
For gene expression, atrogin-1 mRNA levels increased for both treated and control mice between 3 and 7 days, but no differences were observed between groups at these time points (Fig. 2A) . The increase in atrogin-1 mRNA levels continued to 21 days postinjury, with the TGF-␤ inhibitor group having significantly higher atrogin-1 expression than controls ( Fig.  2A) . No differences in type I or type III collagen were observed for any group or time point (Fig. 2, B and C) . For fibroblast markers, no differences in scleraxis were observed over time for either TGF-␤ inhibitor or sham-treated groups or between the groups at any time point (Fig. 2D) , but the expression of FSP-1 and tenomodulin had seemingly opposite responses. FSP-1 levels decreased at 7 and 21 days for both groups compared with the 3-day TGF-␤ inhibitor group (Fig. 2E) , whereas tenomodulin levels were highest at the 21-day time point for both groups (Fig. 2F) . Although FSP-1 and tenomodulin levels changed with time, no differences were observed for either protein between the TGF-␤ inhibitor and control groups, with the exception of higher expression of tenomodulin for the TGF-␤ inhibitor group compared with controls at 21 days (Fig. 2F) .
For histology (Fig. 3) , at 3 and 7 days after injury, both groups demonstrated signs of substantial damage, although the muscles treated with the TGF-␤ inhibitor demonstrated less cellular infiltration and had a grossly improved appearance. At 21 days, the control group returned to a normal appearance, with a healthy ECM and only sporadic centrally located nuclei. However, in the TGF-␤ inhibitor group, the ECM appeared mottled. No significant differences were detected between groups for the size of muscle fibers nor the percentage of centrally located nuclei (Fig. 4) .
DISCUSSION
TGF-␤ plays a central role in promoting inflammation, fibrosis, and muscle atrophy (21, 22, 30) . Nonspecific inhibitors of TGF-␤ signaling have shown some promise in preclinical models of muscle injury. Losartan, an angiotensin II receptor blocker that downregulates Smad2, ERK, and other signal transduction pathway components used by TGF-␤ and other cytokines, improved muscle recovery following muscle laceration, contusion, and cardiotoxin injury (3, 7, 18) . Suramin, a polysulfonated napthylurea molecule that inhibits the binding of several growth factors to their receptors, including TGF-␤ and myostatin, improved muscle regeneration following snake venom cardiotoxin injury, passive stretch injury, and contusion injury (9, 33, 38) . To gain insight into the specific role of TGF-␤ signaling in the recovery of muscle following lengthening contraction-induced injury, and since monoclonal human bioneutralizing TGF-␤ antibodies are currently in clinical trials for a variety of different diseases (37), we chose to use a murine monoclonal antibody to inhibit TGF-␤ following skeletal muscle injury in mice. The combined results from the current study suggest that the targeted inhibition of TGF-␤ following contraction-induced injury in mice prevented normal muscle regeneration. These results are consistent with other studies using anti-inflammatory drugs following muscle injury, where long-term recovery of muscles is impaired when acute inflammation is inhibited (34) .
Previously, we reported that TGF-␤ can potently induce muscle fiber atrophy and weakness likely because of an increase in the expression of the E3 ubiquitin ligase atrogin-1 (30) . In this study, although there was an early increase in P o after inhibition of TGF-␤, by 3 wk control muscles had force values that returned to preinjury values while the TGF-␤ inhibitor group had a persistent decrease in force production. Associated with the observed weakness at 3 wk was a sever- Values are means Ϯ SE; n ϭ 5 mice/group.TGF-␤, transforming growth factor-␤; EDL, extensor digitorum longus; TTPT, time to peak tension; dP/dt, maximum rise in tension; HRT, half-relaxation time. Differences between groups were tested using a two-way ANOVA followed by Holm-Sidak post hoc sorting (P Ͻ 0.05). Differences: a 3 days control; b 3 days TGF-␤ inhibited; c 7 days control. alfold higher expression of atrogin-1 in the TGF-␤ inhibitor group compared with controls, although no quantitative differences in muscle fiber area or percentage of fibers with centrally located nuclei were observed. Combined, these results suggest that the targeted inhibition of TGF-␤ signaling prevents the timely recovery of injured muscle fibers. TGF-␤ is associated with fibrosis and ECM accumulation (21, 22, 30) . Interestingly, no change in type I or III collagen gene expression was observed throughout the study. The gene expression data were supported by immunohistochemistry. While the overall abundance of ECM did not appear to change throughout the study or in response to inhibition of TGF-␤, the ECM appeared mottled and less well organized in the TGF-␤ inhibitor group at 21 days. This mottled ECM may reflect poor repair of injured sarcolemma and a diminished ability to transmit forces laterally (42) , which combined with elevated atrogin-1 expression might suggest the mechanisms for the observed reduction in P o in the TGF-␤ inhibitor group 21 days after injury.
Days Following Injury
Fibroblasts play an important role in the regeneration of injured muscle ECM (35) . TGF-␤ can induce the proliferation of connective tissue fibroblasts through the induction of the bHLH transcription factor scleraxis (25, 30, 31, 40) . While we anticipated that blocking TGF-␤ signaling would decrease scleraxis expression, no differences were observed for either group at any time point. FSP-1 is a marker of fibroblast cells in skeletal muscle and other tissues and plays an important role in cell proliferation (8, 17, 27, 39) . The overall gene expression patterns for FSP-1 were similar for both groups at each time point, with the highest expression occurring 3 days after injury in the TGF-␤-inhibited group. Tenomodulin, a type II transmembrane protein, is highly expressed in embryonic and adult fibroblasts (11) . The precise molecular function of tenomodulin is not well understood, but tenomodulin appears to be associated with both fibroblast proliferation and ECM maturation (11). In the current study, tenomodulin expression was unchanged at 3 or 7 days in both treatment groups. However, tenomodulin expression was higher in both groups at 21 days compared with the 3-and 7-day time points. Additionally, at 21 days after injury, tenomodulin levels were higher for the TGF-␤-inhibited group than controls. The persistent elevation in tenomodulin expression in the 21-day TGF-␤-inhibited group may contribute to delayed ECM healing and maturation response, a hypothesis that is supported by the frayed ECM apparent in immunohistochemistry but remains to be tested directly. This study has several limitations. While a contractioninduced injury protocol is more clinically relevant, it does not generate the widespread and severe damage that occurs with the use of barium chloride or cardiotoxin injury models. Moreover, because of the small amount of tissue available, we measured gene expression and did not directly measure protein content, and changes in gene expression may not be reflective of differences in protein levels. In addition, we did not inhibit TGF-␤ throughout the entire study and chose instead to block TGF-␤ during the acute phases of muscle injury, since this is anticipated to be the time points when TGF-␤ activation is greatest. We did not directly measure the amount of TGF-␤ that was inhibited in this study, but we based our dosing on prior studies that have used 1D11 to effectively antagonize TGF-␤ signaling (1, 10, 36) . While TGF-␤ can directly activate signaling pathways in muscle fibers, TGF-␤ can also modulate the activity of several types of immune cells that play a role in muscle regeneration (12, 19, 46) , but, given the scope of the current study, we did not directly evaluate the TGF-␤-mediated immune cell regulation. Finally, we only measured three time points and used five mice per group, but the time points were chosen based on previous studies to reflect early, intermediate, and full recovery points in the muscle regeneration process (24, 28, 41) . Despite these limitations, this work provided novel and important insights into the role that TGF-␤ signaling plays in the regeneration of muscles following lengthening contraction-induced injuries.
In this study, we tested the hypothesis that the targeted inhibition of TGF-␤ would improve force production and enhance regeneration after contraction-induced injury. Much to our surprise, inhibiting TGF-␤ reduced muscle force production and appeared to impair or at least delay muscle regeneration. While TGF-␤ can signal through several pathways, the results are consistent with recent work that identified an impaired muscle regeneration phenotype in Smad3-deficient mice (13) . Following injury, muscle undergoes a coordinated in- . Differences between groups were tested using a two-way ANOVA followed by Holm-Sidak post hoc sorting (P Ͻ 0.05). No significant differences between groups were detected for muscle fiber area or centrally located nuclei. flammatory phase followed by an anti-inflammatory phase (46) , and both phases may be required for the full recovery of muscle after injury. While the specific effects of TGF-␤ may be adverse to muscle function, through the promotion of ECM deposition and atrophy, as a whole these effects may be necessary for the full regenerative response following injury. These data support that TGF-␤ has an overall beneficial role in muscle recovery following injury by supporting the timely restoration of muscle function. Nonspecific inhibitors of TGF-␤ signaling, such as losartan and suramin, may exert their beneficial effects by targeting a wider class of proatrophy and proinflammatory cytokines such as myostatin, activins, and bone morphogenic proteins. Further studies are necessary to ascertain the mechanisms by which TGF-␤ signaling contributes to the regeneration of muscle following moderate to severe injuries.
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